Plataforma BIOBADASER III

Registro Español de Acontecimientos Adversos de Terapias Dirigidas en Enfermedades Reumáticas

Biobadaser Fase III

Glucocorticoid Use in Rheumatoid Arthritis Patients Initiating Biological or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (b/tsDMARDs) in Real Life: Data from BIOBADASER

28/06/2024

Otero-Varela L, Alvaro-Gracia J, Calvo J, Campos C, Garcia Dorta A, Sánchez-Alonso F, Castrejon I

ACR 2023

Otero-Varela L, Alvaro-Gracias J, Calvo J, Campos C, Garcia Dorta A, Sánchez-Alonso F, Castrejon I. Glucocorticoid Use in Rheumatoid Arthritis Patients Initiating Biological or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (b/tsDMARDs) in Real Life: Data from BIOBADASER [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/glucocorticoid-use-in-rheumatoid-arthritis-patients-initiating-biological-or-targeted-synthetic-disease-modifying-anti-rheumatic-drugs-b-tsdmards-in-real-life-data-from-biobadaser/

https://acrabstracts.org/abstract/glucocorticoid-use-in-rheumatoid-arthritis-patients-initiating-biological-or-targeted-synthetic-disease-modifying-anti-rheumatic-drugs-b-tsdmards-in-real-life-data-from-biobadaser/